

Patient Characteristics and Treatments of Patients in CR versus patients not in CR prior ASCT

Characteristic	not in CR n=219	CR n=55
Follow-up in months [reverse KM] - median (IQR)	130.3 (35.2-164.0)	98.6 (54.3-132.3)
Age at 1st ASCT, years		
median (range) [IQR]	38.2 (18.1-69.6) [27.9-50.4]	30.5 (18.1-63.6) [22.5-48.6]
Patient sex		
	n (%)	n (%)
Male	126 (57.5%)	34 (61.8%)
Female	93 (42.5%)	21 (38.2%)
missing		
Histology		
	n (%)	n (%)
Leiomyosarcoma	47 (21.5%)	7 (12.7%)
Synovial sarcoma	36 (16.4%)	6 (10.9%)
Angiosarcoma*	25 (11.4%)	9 (16.4%)
Liposarcoma	21 (9.6%)	7 (12.7%)
Desmoplastic small round cell tumor	4 (1.8%)	3 (5.5%)
other STS§	86 (39.3%)	23 (41.8%)
Tumor Grading		
	n (%)	n (%)
Grade 1	4 (5.7%)	0 (0%)
Grade 2	11 (15.7%)	7 (29.2%)
Grade 3	55 (78.6%)	17 (70.8%)
missing	149	31
Metastatic disease at diagnosis		
	n (%)	n (%)
No	39 (55.7%)	10 (52.6%)
Yes	31 (44.3%)	9 (47.4%)
Unknown/missing	149	36
Treatment before ASCT		
	n (%)	n (%)
Surgery		
Yes	58 (59.8%)	28 (90.3%)
No	39 (40.2%)	3 (9.7%)
Missing	122	24
Radiotherapy		
Yes	30 (31.6%)	9 (32.1%)
No	65 (68.4%)	19 (67.9%)

Missing	124	27
Chemotherapy		
Yes	92 (92%)	28 (93.3%)
Median no. regimens (range)	1 (1-7)	1 (1-7)
≥ 2 regimens	26	8
None	8 (8%)	2 (6.7%)
Missing	119	25
<hr/>		
Remission status before ASCT	n (%)	n (%)
complete response/no evidence of disease		55 (100%)
partial response	107 (48.9%)	
stable disease	28 (12.8%)	
progressive disease	84 (38.4%)	
<hr/>		
Year of 1st ASCT	n (%)	n (%)
1996-2000	106 (48.4%)	16 (29.1%)
2001-2005	66 (30.1%)	21 (38.2%)
2006-2016	47 (21.5%)	18 (32.7%)
<hr/>		
Preparative regimen	n (%)	n (%)
PEI/CEI	51 (43.2%)	17 (47.2%)
Other Platinum-based	22 (18.6%)	6 (16.7%)
Melphalan-based	28 (23.7%)	11 (30.6%)
Other	17 (14.4%)	2 (5.6%)
missing	101	19
<hr/>		
Remission status after last ASCT	n (%)	n (%)
complete response/no evidence of disease	49 (44.5%)	36 (85.7%)
partial response	18 (16.4%)	1 (2.4%)
stable disease	22 (20%)	0 (0%)
progressive disease	21 (19.1%)	5 (11.9%)
missing	109	13
<hr/>		
Endpoints		
5 year probability of progression-free survival (95% CI)	10.4% (6.5-15.5)	25.9% (14.5-38.9)
5 year probability of overall survival (95% CI)	20% (14.4-26.3)	43.2% (28.7-56.9)
Median progression-free survival, months (95% CI)	7.2 (5.8-8.5)	14.1 (10.7-17.5)
Median overall survival, months (95% CI)	17.8 (15.8-19.9)	44.1 (15.3-72.9)